ADVERTISEMENT

Jubilant Pharmova - Strong CDMO, Radiopharma Businesses; Undemanding Valuation: Nirmal Bang

Radiopharma business is back to pre-Covid level and is expected to grow in double digits with new launches, ramp-up in Ruby-fill.

<div class="paragraphs"><p>Generics manufactured by Jubilant Pharmova (Source: Company website).&nbsp;</p></div>
Generics manufactured by Jubilant Pharmova (Source: Company website). 
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. 
To continue reading this story
You must be an existing Premium User
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit